$BDTX News

Black Diamond Therapeutics: Positive Phase 2 Results Offer An Upside

Black Diamond Therapeutics Touts Silevertinib Lung Cancer Data, Eyes FDA Path

What's Going On With Black Diamond Therapeutics Stock Tuesday?

Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference

Black Diamond Therapeutics Lung Cancer Drug Shows 15.2-Month PFS in Phase 2 Study

Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations

Black Diamond Therapeutics' Silevertinib Shows 15.2-Month Median PFS And 60% Response Rate With CNS Activity In EGFR Non-Classical Mutation NSCLC Phase 2 Study

Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC

Black Diamond Therapeutics (NASDAQ:BDTX) Is In A Good Position To Deliver On Growth Plans

Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Black Diamond Therapeutic Q1 EPS $(0.16) Misses $(0.03) Estimate

BTIG Maintains Buy on Black Diamond Therapeutic, Raises Price Target to $11

Implied Volatility Surging for Black Diamond Therapeutics Stock Options

Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting

Black Diamond To Present Phase 2 Data Of Silevertinib In Recurrent EGFRm NSCLC Patients And Trial-In-Progress Poster On Randomized Phase 2 Trial Of Silevertinib In EGFRvIII-Positive GBM At 2026 ASCO

Why Is Black Diamond (BDTX) Up 19.3% Since Last Earnings Report?

BDTX and Brain Metastases: Why CNS Activity Could Matter in 2026

Wedbush Bullish on Black Diamond Therapeutics (BDTX) Following Progress in Silevertinib Program

Black Diamond Therapeutics: Market Is Yawning About These Data, But I See Opportunity

Wedbush Maintains Outperform on Black Diamond Therapeutic, Raises Price Target to $14